Reference:USA 21 CFR Part 312 09-Apr-2025 § 312.33 (a) (3)
From GxPlex
| Document information | |
|---|---|
| Reference | USA 21 CFR Part 312 09-Apr-2025 |
| Validity area | USA |
| Scope(s) | HM |
| Document name | 21 CFR Part 312 |
| Version / Revision | 09-Apr-2025 |
| Status | Current |
| Document type | Legal act |
| Language(s) | EN |
| Description | Title 21 —Food and Drugs
Chapter I —Food and Drug Administration, Department of Health and Human Services Subchapter D—Drugs for Human Use Part 312 Investigational New Drug Application https://www.ecfr.gov/current/title-21 |
| Official source | Official link |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
| Reference Details | |
|---|---|
| Module | Module 6 — Unit 6.4.2 |
| Scope | HM |
| Document part | § 312.33
(a) (3) |
| Language | EN |
| Original entry by | Florian Adragna |
| Contributors | |
| Tags | Interim report, Sponsor, Investigational drug (IMP), FDA |
Content
§ 312.33 Annual reports. A sponsor shall within 60 days of the anniversary date that the IND went into effect, submit a brief report of the progress of the investigation that includes: […] (a) […] (3) If the study has been completed, or if interim results are known, a brief description of any available study results. [...]
